TopeffJ M, EllsworthH, WillhiteL A, BanghS A, EdwardsE M and ColeJ B. 2011. A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clin Toxicol (Phila), 49: 526
2.
US Department of Justice. February 2011. 2,5-Dimethoxy-4-(n)-propylthio- phenethylamine (street names: 2C-T-7, Blue Mystic, T7, Beautiful, Tripstay, Tweety-Bird Mescaline), Johnstown, PA: US Department of Justice.
3.
US Department of Justice. 2011. Drug alert watch: 2C-E causes death in Minnesota, Johnstown, PA: US Department of Justice. March 25
4.
MeyerM R and MaurerH H. 2010. Metabolism of designer drugs of abuse: an updated review. Curr Drug Metab., 11: 468–482.
5.
SandersB, LankenauS E, BloomJ J and HathaziD. 2008. Research chemicals”: tryptamine and phenethylamine use among high-risk youth. Subst Use Misuse, 43: 389–402.
6.
de BoerD and BosmanI. 2004. A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs. Pharm World Sci., 26: 110–113.
7.
US Department of Justice. 2001. Information bulletin: 2C-B (Nexus) reappears on the drug scene, Johnstown, PA: US Department of Justice. May
8.
ArnoldT C, HindmanB W, WalkerA L and RyanM L. 2005. Death from ingestion of 2C-T-21: A novel phenethylamine. Clin Toxicol (Phila), 43: 662–663.
9.
McGraneO., SimmonsJ, JacobsonE and SkinnerC. 2011. Alarming trends in a novel class of designer drugs. J Clin Toxicol, 1: 2
10.
TopeffJ M, ColeJ B, EdwardsE M, BanghS A and EllsworthH. 2011. The use of intravenous fat emulsion as an adjunct to standard ACLS in the resuscitation of a patient in cardiopulmonary arrest after 2C-E use. Clin Toxicol (Phila), 49: 541
